Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMMP65N)

Drug Name
Sertindole Drug Info
Synonyms
SerLect; Serdolect; Sertindol; Sertindolum; Sertindole hydrochloride; Lu 23-174; S-1991; SerLect (TN); Serdolect (TN); Serlect (TN); Sertindol [INN-Spanish]; Sertindole [USAN:INN]; Sertindolum [INN-Latin]; Lu-23-174; Sertindole (USAN/INN); 1-(2-(4-(5-Chloro-1-(4-fluorophenyl)-1H-indole-3-yl)-1-piperidinyl)ethyl)-2-imidazolidinone; 1-(2-(4-(5-Chloro-1-(p-fluorophenyl)indol-3-yl)piperidino)ethyl)-2-imidazolidinone; 1-(2-(4-(5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl)-1-piperidinyl)ethyl)-2-imidazolidinone; 1-(2-{4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]piperidin-1-yl}ethyl)imidazolidin-2-one; 1-[2-[4-[5-Chloro-1-(p-fluorophenyl)indol-3-yl]piperidino]ethyl]-2-imidazolidinone; 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one; 1-[2-[4-[5-chloro-1-(4-fluorophenyl)indol-3-yl]piperidin-1-yl]ethyl]imidazolidin-2-one
Therapeutic ClassAntipsychotic Agents
Cross-matching ID
PubChem CID
60149
ChEBI ID
CHEMBL12713
CAS Number
CAS 106516-24-9
TTD Drug ID
D0OS6O
VARIDT Drug ID
DR00815
INTEDE Drug ID
DR1475

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
ECM-receptor interaction 2.16 0.00e+0 80/88 (90.91%) CD44;SPP1;THBS2;...
Ferroptosis 1.97 5.07e-3 36/41 (87.8%) FTH1;SLC39A8;STEAP3;...
Pentose phosphate pathway 1.83 4.39e-2 25/30 (83.33%) FBP1;PFKM;TKT;...
Influenza A -1.56 4.98e-2 156/172 (90.7%) IFNAR2;TPSB2;DDX58;...
RIG-I-like receptor signaling pathway -1.57 4.99e-2 64/70 (91.43%) MAP3K1;MAPK8;TRAF6;...
Natural killer cell mediated cytotoxicity -1.62 3.50e-2 99/131 (75.57%) FASLG;KIR2DL3;IFNA16;...
Tuberculosis -1.63 3.48e-2 159/180 (88.33%) C3;CLEC7A;IFNG;...
Systemic lupus erythematosus -1.67 2.67e-2 45/135 (33.33%) C3;IFNG;HLA-DOA;...
Thermogenesis -1.67 2.80e-2 173/232 (74.57%) MAP3K5;ATP5MF;RPS6KB1;...
Amyotrophic lateral sclerosis -1.68 2.74e-2 267/364 (73.35%) PSMD9;DNAH17;PSMA4;...
Chemokine signaling pathway -1.70 2.35e-2 163/192 (84.9%) SHC1;CXCL11;AKT1;...
Autoimmune thyroid disease -1.72 2.14e-2 46/53 (86.79%) HLA-DOA;HLA-DRA;HLA-DOB;...
Huntington disease -1.74 1.78e-2 233/306 (76.14%) DNAH6;POLR2D;PSMD8;...
Th17 cell differentiation -1.81 1.11e-2 95/107 (88.79%) IFNG;HLA-DOA;HSP90AA1;...
Inflammatory bowel disease -1.82 9.82e-3 58/65 (89.23%) TLR5;TNF;IL12A;...
Antigen processing and presentation -1.84 9.82e-3 60/78 (76.92%) TNF;CD8A;HSPA4;...
Viral protein interaction with cytokine and cytokine re... -1.86 7.37e-3 84/100 (84%) TNF;CXCL11;CCR7;...
Staphylococcus aureus infection -1.88 7.14e-3 72/95 (75.79%) KRT15;KRT9;C3;...
Th1 and Th2 cell differentiation -1.90 4.91e-3 80/92 (86.96%) JAG2;PRKCQ;IL13;...
Allograft rejection -1.93 4.37e-3 32/38 (84.21%) IFNG;HLA-DOA;HLA-DRA;...
Leishmaniasis -1.94 4.91e-3 67/77 (87.01%) TNF;IL12A;TLR2;...
Asthma -2.04 1.40e-3 25/31 (80.65%) IL9;FCER1A;CCL11;...
Parkinson disease -2.05 1.64e-3 176/249 (70.68%) SEM1;PRKACA;COX6A2;...
Prion disease -2.09 0.00e+0 209/273 (76.56%) STIP1;NDUFA5;NDUFS3;...
Graft-versus-host disease -2.10 0.00e+0 32/42 (76.19%) TNF;KIR2DL1;KIR3DL1;...
Oxidative phosphorylation -2.10 0.00e+0 93/133 (69.92%) COX11;ATP6V0E1;SDHA;...
Proteasome -2.13 0.00e+0 44/46 (95.65%) SEM1;PSMD8;PSME3;...
Type I diabetes mellitus -2.33 0.00e+0 38/43 (88.37%) LTA;IFNG;CPE;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H